Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that TTF-1 promotes SCLC growth and contributes to neuroendocrine and antiapoptotic gene expression by partly coordinating with ASCL1.
|
31782890 |
2020 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The association between 103 SNPs in 58 ASCL1 target genes and the response to chemotherapy and survival of patients with SCLC were analyzed.
|
31691490 |
2020 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmacological co-targeting of ASCL1 and IGF-1R results in markedly synergistic effects in ASCL1<sup>High</sup> SCLC in vitro and in mouse models.
|
31324758 |
2019 |
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to investigate the expression of DLL3 and ASCL1 in resected SCLC samples using immunohistochemical analysis.
|
31068386 |
2019 |
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Several lines of evidence, from SCLC primary human tumours, patient-derived xenografts, cancer cell lines and genetically engineered mouse models, appear to be converging on a new model of SCLC subtypes defined by differential expression of four key transcription regulators: achaete-scute homologue 1 (ASCL1; also known as ASH1), neurogenic differentiation factor 1 (NeuroD1), yes-associated protein 1 (YAP1) and POU class 2 homeobox 3 (POU2F3).
|
30926931 |
2019 |
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Wnt11 controlled NE differentiation, cell proliferation, and E-cadherin expression under the regulation of Ascl1 in SCLC cell lines.
|
31231131 |
2019 |
Small cell carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three correspond to known subtypes (SCLC-A, SCLC-N, and SCLC-Y), while the fourth is a previously undescribed ASCL1+ neuroendocrine variant (NEv2, or SCLC-A2).
|
31671086 |
2019 |
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In particular, the delta-like protein 3 (DLL3), a Notch inhibitory ligand whose expression is directly related to the key neuroendocrine transcription factor ASCL1, was found to be expressed in ~85% of SCLCs, while it exhibits minimal to absent surface expression in normal lungs.
|
30968324 |
2019 |
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we found that exposure to the selective LSD1 inhibitor ORY-1001 activated the NOTCH pathway, resulting in the suppression of the transcription factor ASCL1 and the repression of SCLC tumorigenesis.
|
30723171 |
2019 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amiloride inhibited growth of ASCL1-dependent SCLC more strongly than ASCL1-independent SCLC in vitro and slowed growth of ASCL1-driven SCLC in xenografts.
|
29413762 |
2018 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings shine light on a regulatory axis in SCLC consisting of ASCL1/TTF-1/NFIB that potentially contributes to the tumourigenesis of SCLC.
|
29876935 |
2018 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
IMPDH inhibition reduced RNA polymerase I-dependent expression of pre-ribosomal RNA and potently suppressed ASCL1<sup>Low</sup> cell growth in culture, selectively reduced growth of ASCL1<sup>Low</sup> xenografts, and combined with chemotherapy to improve survival in genetic mouse models of ASCL1<sup>Low</sup>/MYC<sup>High</sup> SCLC.
|
30043754 |
2018 |
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The proneural factor, ASCL1, was specifically up-regulated in SCLC which is known to have a neuroendocrine phenotype.
|
29866045 |
2018 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a case-control cohort matched for basic clinical factors, expression of ProGRP, synaptophysin, chromogranin A, and ASCL1 was significantly decreased in TTF-1-negative SCLC samples.
|
29787820 |
2018 |
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The Shh signaling pathway activates INSM1 expression through N-myc and Ascl1 in aggressive SCLC.
|
29501727 |
2018 |
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nuclear ASCL1 expression was present in SCLC but absent or barely present in adenocarcinoma in 7 cases.
|
30429033 |
2018 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the other hand, achaete-scute complex homologue 1 (ASCL1), negatively regulated by Notch signaling, is a lineage-specific gene of SCLC, and functions to promote neuroendocrine differentiation as well as EMT.
|
27785690 |
2017 |
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High expression of the inhibitory Notch ligand Delta-like protein 3 (DLL3) in most SCLCs has been linked to expression of Achaete-scute homologue 1 (ASCL1; also known as ASH-1), a key transcription factor driving SCLC oncogenesis; encouraging preclinical and clinical activity has been demonstrated for an anti-DLL3-antibody-drug conjugate.
|
28534531 |
2017 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, we also observed ASCL1 governed functional networks that are distinct to glioma and SCLC.
|
28742165 |
2017 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, ASCL1 and NEUROD1 distinguish heterogeneity in SCLC with distinct genomic landscapes and distinct gene expression programs.
|
27452466 |
2016 |
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of the INSM1 gene in adenocarcinoma cell lines (H358 and H1975) induced the expression of ASCL1, brain-2 (BRN2), chromogranin A, synaptophysin, and neural cell adhesion molecule 1; in contrast, knockdown of the INSM1 gene by siRNA in SCLC (H69 and H889) decreased their expression.
|
26482608 |
2015 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
CTD_human |
The importance of ASCL1 as a potential driver oncogene in SCLC is further underscored by the observation that ASCL1 is overexpressed in >50% of SCLC specimens, an extent greater than that observed for other putative oncogenes (MYC, MYCN, and SOX2) previously implicated in SCLC.
|
26253517 |
2015 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The importance of ASCL1 as a potential driver oncogene in SCLC is further underscored by the observation that ASCL1 is overexpressed in >50% of SCLC specimens, an extent greater than that observed for other putative oncogenes (MYC, MYCN, and SOX2) previously implicated in SCLC.
|
26253517 |
2015 |
Small cell carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We determined that achaete-scute homolog 1 (ASCL1), a transcription factor required for proper development of pulmonary neuroendocrine cells, is essential for the survival of a majority of lung cancers (both SCLC and NSCLC) with neuroendocrine features.
|
25267614 |
2014 |
Small cell carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings suggest that BRN2 is a higher level regulator than ASCL1 and ND1 and BRN2 might be involved in aggressiveness of SCLC.
|
23530560 |
2013 |